{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:49:59Z","timestamp":1792028999410,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-024-05120-w","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:02:44Z","timestamp":1728885764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial"],"prefix":"10.1186","volume":"28","author":[{"given":"Mark C.","family":"Chappell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Schaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Sevransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah K.","family":"Hinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish K.","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Vitamin C, Thiamine, Steroids in Sepsis (VICTAS) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"5120_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1055\/s-0041-1733915","volume":"42","author":"J Weinberger","year":"2021","unstructured":"Weinberger J, Klompas M, Rhee C. What is the utility of measuring lactate levels in patients with sepsis and septic shock? Semin Respir Crit Care Med. 2021;42:650\u201361.","journal-title":"Semin Respir Crit Care Med"},{"key":"5120_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CCM.0000000000005143","volume":"50","author":"M Jeyaraju","year":"2022","unstructured":"Jeyaraju M, McCurdy MT, Levine AR, Devarajan P, Mazzeffi MA, Mullins KE, et al. Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically Ill patients. Crit Care Med. 2022;50:50\u201360.","journal-title":"Crit Care Med"},{"key":"5120_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202:1253\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"5120_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","volume":"47","author":"PJ Gleeson","year":"2019","unstructured":"Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Van Meerhaeghe T, Brimioulle S, et al. Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit Care Med. 2019;47:152\u20138.","journal-title":"Crit Care Med"},{"key":"5120_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/CCM.0000000000006095","volume":"52","author":"LW Busse","year":"2024","unstructured":"Busse LW, Schaich CL, Chappell MC, McCurdy MT, Staples EM, Ten Lohuis CC, et al. Association of active renin content with mortality in critically Ill patients: a post hoc analysis of the Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) trial. Crit Care Med. 2024;52:441\u201351.","journal-title":"Crit Care Med"},{"key":"5120_CR6","doi-asserted-by":"publisher","first-page":"171201","DOI":"10.1016\/j.peptides.2024.171201","volume":"176","author":"CL Schaich","year":"2024","unstructured":"Schaich CL, Leisman DE, Goldberg MB, Filbin MR, Khanna AK, Chappell MC. Dysfunction of the renin-angiotensin-aldosterone system in human septic shock. Peptides. 2024;176:171201.","journal-title":"Peptides"},{"key":"5120_CR7","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310:H137\u201352.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"5120_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccc.2018.11.002","volume":"35","author":"L Bitker","year":"2019","unstructured":"Bitker L, Burrell LM. Classic and nonclassic renin-angiotensin systems in the critically Ill. Crit Care Clin. 2019;35:213\u201327.","journal-title":"Crit Care Clin"},{"key":"5120_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","volume":"10","author":"T Kahlon","year":"2022","unstructured":"Kahlon T, Carlisle S, Otero Mostacero D, Williams N, Trainor P, DeFilippis AP. Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics. JACC Heart Fail. 2022;10:699\u2013713.","journal-title":"JACC Heart Fail"},{"key":"5120_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"5120_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrgastro.2016.168","volume":"14","author":"P Strnad","year":"2017","unstructured":"Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14:55\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5120_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4166\/kjg.2020.75.4.182","volume":"75","author":"TS Kim","year":"2020","unstructured":"Kim TS, Choi DH. Liver Dysfunction in Sepsis. Korean J Gastroenterol. 2020;75:182\u20137.","journal-title":"Korean J Gastroenterol"},{"key":"5120_CR13","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1161\/ATVBAHA.121.316590","volume":"41","author":"M Kukida","year":"2021","unstructured":"Kukida M, Cai L, Ye D, Sawada H, Katsumata Y, Franklin MK, et al. Renal angiotensinogen is predominantly liver derived in nonhuman primates. Arterioscler Thromb Vasc Biol. 2021;41:2851\u20133.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5120_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.kint.2020.07.047","volume":"99","author":"DE Leisman","year":"2021","unstructured":"Leisman DE, Fernandes TD, Bijol V, Abraham MN, Lehman JR, Taylor MD, et al. Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury. Kidney Int. 2021;99:148\u201360.","journal-title":"Kidney Int"},{"key":"5120_CR15","first-page":"252","volume":"10","author":"J Li","year":"1996","unstructured":"Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10:252\u201364.","journal-title":"Mol Endocrinol"},{"key":"5120_CR16","doi-asserted-by":"publisher","first-page":"25095","DOI":"10.1016\/S0021-9258(19)74575-X","volume":"268","author":"C Klett","year":"1993","unstructured":"Klett C, Nobiling R, Gierschik P, Hackenthal E. Angiotensin II stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA. J Biol Chem. 1993;268:25095\u2013107.","journal-title":"J Biol Chem"},{"key":"5120_CR17","doi-asserted-by":"publisher","first-page":"e2211370119","DOI":"10.1073\/pnas.2211370119","volume":"119","author":"DE Leisman","year":"2022","unstructured":"Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, et al. Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci. 2022;119:e2211370119.","journal-title":"Proc Natl Acad Sci"},{"key":"5120_CR18","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/HYPERTENSIONAHA.120.16724","volume":"77","author":"MC Chappell","year":"2021","unstructured":"Chappell MC, Pirro NT, South AM, Gwathmey TM. Concerns on the specificity of commercial ELISAs for the measurement of angiotensin (1\u20137) and angiotensin II in human plasma. Hypertension. 2021;77:e29\u201331.","journal-title":"Hypertension"},{"key":"5120_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419\u201330.","journal-title":"N Engl J Med"},{"key":"5120_CR20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949\u201357.","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-05120-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:02:35Z","timestamp":1734332555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-05120-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5120"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-05120-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4946900\/v1","asserted-by":"object"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was reviewed and approved in April of 2021 with a waiver of consent by the Wake Forest University School of Medicine institutional review board (00073908) and all procedures were followed in accordance with local ethics standards and the Helsinki Declaration of 1975.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AKK has previously received consulting fees from La Jolla Pharma, including grant funding for the ATHOS3 trial. He has also previously received consulting fees from Innoviva Therapeutics and Viatris Pharmaceuticals. The other authors declare that there are no competing financial interests in the work described in the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}